Axsome Therapeutics Reports Accelerating AUVELITY Prescriptions Following Alzheimer's Agitation Launch
Axsome Therapeutics executive leadership reported accelerating prescription growth for AUVELITY, driven by a sales force expansion and rising demand in Alzheimer's disease agitation.

